Anticancer Drugs Course
This course equips oncology professionals with practical skills to master first-line EGFR TKI treatments for EGFR-mutant NSCLC. Participants learn to manage toxicities effectively, handle resistance challenges, optimise patient outcomes, and communicate treatment plans clearly using evidence-based approaches and up-to-date guidelines.

from 4 to 360h flexible workload
valid certificate in your country
What will I learn?
Gain a practical overview of first-line systemic treatments for EGFR-mutated NSCLC, covering targeted therapies, chemo-immunotherapy, and chemotherapy. Master drug mechanisms, dosing schedules, toxicity management, resistance mechanisms, second-line choices, monitoring protocols, and patient communication skills for evidence-based decisions in oncology practice.
Elevify advantages
Develop skills
- Select EGFR TKIs for first-line treatment based on latest trial data.
- Plan resistance assessments with imaging, re-biopsy, and liquid biopsy.
- Develop second-line plans matching resistance to targeted, chemo, or trial therapies.
- Prevent and manage EGFR TKI toxicities like rash, diarrhoea, ILD, and cytopenias.
- Counsel patients clearly on treatment goals, side effects, and progression strategies.
Suggested summary
Before starting, you can change the chapters and workload. Choose which chapter to start with. Add or remove chapters. Increase or decrease the course workload.What our students say
FAQs
Who is Elevify? How does it work?
Do the courses have certificates?
Are the courses free?
What is the course workload?
What are the courses like?
How do the courses work?
What is the duration of the courses?
What is the cost or price of the courses?
What is an EAD or online course and how does it work?
PDF Course